Jazz Pharmaceuticals v. Lupin: Xywav® Patent Case Consolidated in NJ
Jazz Pharmaceuticals Ireland Limited brought an infringement action against Lupin Limited and its affiliates over a proposed generic version of Xywav®, asserting US11986446B2. Within 99 days of filing, the court consolidated this action with two related cases — signalling coordinated, large-scale ANDA litigation ahead.
Multi-front ANDA battle over Jazz’s low-sodium oxybate franchise
On 27 August 2024, Jazz Pharmaceuticals Ireland Limited filed suit against Lupin Limited, Lupin Pharmaceuticals, Inc., and Lupin, Inc. in the District of New Jersey, asserting US11986446B2 in connection with Lupin’s ANDA filing seeking approval for a generic version of Xywav® (low-sodium mixed oxybate oral solution). The case was assigned No. 2:24-cv-08786 and represented one of at least three parallel actions Jazz was pursuing against Lupin over the same product franchise.
On 4 December 2024 — just 99 days after filing — the court ordered consolidation of this action with Civil Action Nos. 21-14271 and 24-8785 for all purposes, including discovery, case management, and trial. Consolidation is a procedural step, not a merits ruling; it means all three actions will proceed as a unified docket, with coordinated discovery and a single trial schedule, subject to any further court order.
The consolidation timeline is consistent with standard Hatch-Waxman litigation practice, where courts routinely merge related ANDA cases involving the same NDA holder and generic applicant to avoid duplicative proceedings. The underlying merits dispute — whether Lupin’s ANDA product would infringe US11986446B2 — remains fully open. The public record does not yet disclose claim construction positions, invalidity contentions, or any settlement discussions.
Filing to Case Consolidated in 99 days
99 days from filing to consolidation — ANDA cases typically consolidate within 90–120 days
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Jazz Pharmaceuticals Ireland Limited | Individual | Specialty pharma — holder of US11986446B2 covering Xywav® low-sodium oxybateSearch in Eureka ↗ |
| Defendant | Lupin Limited | Individual | Global generic pharmaceutical manufacturer and its U.S. affiliates seeking ANDA approvalSearch in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order merges Civil Action Nos. 21-14271, 24-8785, and 24-8786 ‘for all purposes, including discovery, case management, and trial.’ This language is broad and suggests the court intends a single unified proceeding — not merely coordinated scheduling. No merits determination has been made. The order preserves the court’s discretion to modify consolidation terms by the phrase ‘subject to further order of the Court’, indicating the structure remains flexible as the docket develops.
US11986446B2 — Low-sodium oxybate oral solution (Xywav®)
US11986446B2, filed under application number 17/562787, protects formulations and/or methods relating to Xywav® — Jazz Pharmaceuticals’ low-sodium mixed oxybate oral solution approved for cataplexy and excessive daytime sleepiness in narcolepsy, and idiopathic hypersomnia. The low-sodium profile differentiates Xywav® from its predecessor Xyrem® (sodium oxybate), which carries a high sodium burden clinically significant for patients with cardiovascular risk. Patent protection in this space typically covers formulation composition, sodium content parameters, and dosing methods.
Xywav® generated substantial revenue for Jazz, making US11986446B2 a commercially critical asset. The patent’s inclusion in ANDA litigation alongside at least two other asserted patents suggests Jazz has layered its IP protection across multiple aspects of the product. For generic manufacturers, the key strategic question is whether any claim in the Lupin ANDA product can be designed around without triggering infringement — a question that hinges on the specific claim scope, which remains to be litigated in the consolidated proceeding.
Should you run an FTO against US11986446B2 for oxybate products?
Any pharmaceutical company developing a low-sodium oxybate formulation — whether for narcolepsy, idiopathic hypersomnia, or adjacent CNS indications — should treat US11986446B2 as a primary FTO target. The fact that Jazz is asserting this patent in multi-front ANDA litigation signals it views the claims as commercially valuable and enforceable. R&D and regulatory teams preparing ANDA or 505(b)(2) filings for oxybate products should assess claim scope before finalising formulation specifications.
PatSnap Eureka’s FTO Search Agent can map US11986446B2’s claim scope against your candidate formulation, identify continuation applications in the same family, and flag any additional Jazz Pharmaceuticals patents asserted in the consolidated NJ docket. Use Eureka to build a full oxybate patent landscape across Jazz’s portfolio before committing to development spend — consolidation of three cases signals a deep and actively defended IP estate.
Run a freedom-to-operate analysis on US11986446B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman oxybate patent cases in New Jersey
Explore related ANDA infringement actions involving oxybate formulation patents litigated in the District of New Jersey, including other Jazz Pharmaceuticals enforcement actions.
What this consolidation signals for the Xywav® IP landscape
Three parallel ANDA suits merged into one docket — Jazz is mounting a coordinated, multi-patent defence of its low-sodium oxybate franchise.
Consolidation accelerates discovery but raises litigation cost for all parties
Merging three related ANDA actions into one docket means Lupin faces a unified discovery burden across all asserted patents simultaneously. For Jazz, consolidation reduces the risk of inconsistent rulings but increases the complexity of managing a single large trial. Generic entrants should model for an extended pre-trial period before any market entry decision can be made.
Xywav® patent estate likely spans multiple filing dates — watch for blocking continuation patents
The involvement of a 2021-vintage case (21-14271) alongside 2024 filings suggests Jazz has been asserting iteratively updated patent coverage. US11986446B2, with application No. 17/562787, is consistent with a continuation strategy. Competitors developing low-sodium oxybate alternatives should map the full continuation chain before committing to formulation design.
Limited v Lupin — key questions answered
The case was consolidated with related Civil Action Nos. 21-14271 and 24-8785 by court order on 4 December 2024, just 99 days after filing. No merits determination was made. The consolidated actions will proceed together for discovery, case management, and trial in the District of New Jersey.
In case 2:24-cv-08786, Jazz asserts US11986446B2 (application No. 17/562787) against Lupin’s proposed generic version of Xywav® (low-sodium mixed oxybate oral solution). Additional patents are likely asserted in the related consolidated actions, but the full patent list for those cases is not reflected in this case record.
Consolidation merges multiple related cases into a single docket for coordinated discovery, case management, and trial. It does not resolve any patent infringement or validity issues on the merits. It is a procedural efficiency measure that avoids duplicative proceedings and inconsistent rulings across parallel ANDA actions involving the same parties and product.
The defendants are Lupin Limited (the Indian parent entity), Lupin Pharmaceuticals, Inc. (the U.S. subsidiary), and Lupin, Inc. Naming multiple affiliated entities is standard practice in ANDA litigation to ensure the full corporate group is bound by any injunction or judgment that may ultimately issue.
Xywav® is Jazz Pharmaceuticals’ low-sodium mixed oxybate oral solution, approved for cataplexy and excessive daytime sleepiness associated with narcolepsy and for idiopathic hypersomnia. It is a successor to Xyrem® (sodium oxybate) with a lower sodium burden. As a commercially significant branded drug, it is subject to Hatch-Waxman ANDA challenges from generic manufacturers seeking early market entry, triggering patent litigation from the NDA holder.
PatSnap Eureka searches patents and litigation data to answer instantly.